Table 1.
Clinical Characteristics of Study Participants With and Without Any Clinically Significant Cardiac Arrhythmias Diagnosed During ECG Monitoring
| Characteristic | Total (n=28) |
|---|---|
| Age (SD), y | 53.9 (12.5) |
| Male, n (%) | 16 (57.1) |
| Black, n (%) | 27 (96.4) |
| Body mass index (SD), kg/m2 | 29.4 (7.4) |
| Cause of ESKD: | |
| Glomerulonephritis, n (%) | 3 (10.7) |
| Hypertension, n (%) | 5 (17.9) |
| Diabetes mellitus, n (%) | 12 (42.9) |
| HIV/other/genetic/obstruction, n (%) | 7 (25.0) |
| Unknown, n (%) | 1 (3.6) |
| Hypertension, n (%) | 28 (100) |
| Diabetes mellitus, n (%) | 16 (57.1) |
| Coronary artery disease, n (%) | 8 (28.6) |
| Heart failure, n (%) | 9 (32.1) |
| Cerebrovascular disease, n (%) | 8 (28.6) |
| History of atrial fibrillation, n (%) | 10 (35.7) |
| Hypercholesterolemia, n (%) | 19 (67.9) |
| Smoker current or former, n (%) | 15 (53.6) |
| Drinker current or former, n (%) | 23 (82.1) |
| Use of β‐blockers, n (%) | 19/23 (82.6) |
| Charlson comorbidity index (SD) | 5.5 (2.2) |
| Dialysis recovery time (SD), min | 15.9 (3.3) |
| LV ejection fraction (SD), % | 70.3 (9.3) |
| LV internal dimension diastole (SD), cm | 5.3 (0.7) |
| LV internal dimension systole (SD), cm | 3.1 (0.7) |
| LV mass index (SD), g/m2 | 146.0 (53.2) |
| LV hypertrophy, n (%) | 17 (70.8) |
| 3‐mo averaged calcium (SD), mg/dL | 8.52 (0.65) |
| 3‐mo averaged potassium (SD), mEq/L | 4.34 (0.39) |
| 3‐mo averaged intradialytic weight change (SD), kg | 2.09 (0.97) |
| 3‐mo averaged dialysis bath calcium concentration (SD), mmol/L | 2.4 (0.2) |
| 3‐mo averaged dialysis bath potassium concentration (SD), mmol/L | 2.2 (0.4) |
Three‐month‐averaged values are from the start of dialysis. ESKD indicates end‐stage kidney disease; HIV, human immunodeficiency virus; LV, left ventricular.